miR-199a-3p Inhibitor Delivered Through Nano-Drug Delivery Systems Suppresses Tumor Cell Survival and Metastasis

Gastric cancer (GC) is a life-threatening malignant tumor present in the digestive tract. In this study the connection of miR-199a-3p, which is a gene abnormally expressed in GC, was analyzed along with the pathological parameters as well as the prognosis of GC patients. Moreover, the influence of miR-199a-3p inhibitor delivered through the nano-drug delivery system (NDDS) was studied in regard of GC cell survival and metastasis, seeking to reveal its potential treatment effect. During the conduction of the study, high miR-199a-3p expression was detected in GC tissues, sera, and cells along with its value for GC screening and pathological progression. In molecular research, polylactic-glycolic acid (PLGA) nanoparticles (NPs)-miRNA complexes that shaped like symmetrical spheres under the scanning electron microscope (SEM) were prepared to increase or decrease the levels of miR-199a-3p. The GC cell survival and metastasis was remarkably facilitated by the elevated miR-199a-3p, and its knockdown produced an opposite effect to markedly inhibit GC cell survival and metastasis. In conclusion, the expression in GC patients was increased by miR-199a-3p and the ability of its inhibitor delivered through the NDDS was demonstrated to control the survival and metastasis of GC cells.